2022 World Conference on Lung Cancer (ePosters)-EP08.02-042. EGFR-TKI +/- Antiangiogenics for EGFR-mutated Advanced NSCLC

Pdf Summary

This document is a summary of a study on the effectiveness of different treatment combinations in patients with EGFR-mutated Non-Small Cell Lung Cancer (NSCLC). The study compared the use of first-generation EGFR tyrosine kinase inhibitors (TKIs) alone, first-generation EGFR-TKIs plus antiangiogenic agents (anti-VEGF), third-generation EGFR-TKIs alone, and third-generation EGFR-TKIs plus anti-VEGF. The main outcomes measured were Progression-Free Survival (PFS) and Overall Survival (OS).<br /><br />The study found that the addition of antiangiogenic agents to either first- or third-generation EGFR-TKIs did not significantly improve OS. However, third-generation EGFR-TKI monotherapy provided the best PFS benefit. The combination of antiangiogenic agents with EGFR-TKIs did not enhance this benefit and increased the rates of toxicities such as hypertension and proteinuria.<br /><br />The hazard ratios for PFS and OS were calculated for each treatment combination. The hazard ratios for PFS were most favorable for third-generation EGFR-TKI monotherapy, while the hazard ratios for OS did not show significant differences between the treatment combinations.<br /><br />In conclusion, this study suggests that the combination of EGFR-TKIs with antiangiogenic agents does not improve OS in patients with EGFR-mutated NSCLC. Third-generation EGFR-TKI monotherapy provides the best PFS benefit. However, it is important to note that the addition of antiangiogenic agents to EGFR-TKIs increases the risk of certain toxicities. Further research is needed to fully understand the optimal treatment approach for this patient population. For more information, the presenter can be contacted at laercio.dasilva@nih.gov.

Asset Subtitle

Laercio Lopes DaSilva

Meta Tag

Speaker Laercio Lopes DaSilva

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

EGFR-mutated Non-Small Cell Lung Cancer

treatment combinations

first-generation EGFR tyrosine kinase inhibitors

antiangiogenic agents

third-generation EGFR-TKIs

Progression-Free Survival

Overall Survival

hazard ratios

toxicities

optimal treatment approach